Immunovant's stock fell despite positive batoclimab study results. The company focuses on IMVT-1402 for autoimmune conditions, deferring regulatory decisions.
Immunovant's stock fell despite positive batoclimab study results. The company focuses on IMVT-1402 for autoimmune conditions, deferring regulatory decisions.
Bolloré shares slide following profitability decline in fiscal 2024. Shares dropped by 7.5% amidst significant decreases in adjusted EBITA and slight revenue.
